Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

Understanding individual differences in the susceptibility to metabolic side effects as a response to antipsychotic therapy is essential to optimize the treatment of schizophrenia. Here we perform genomewide association studies (GWAS) to search for genetic variation affecting the susceptibility to m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adkins, Daniel E., Åberg, Karolina, McClay, Joseph L., Bukszár, József, Zhao, Zhongming, Jia, Peilin, Stroup, T. Scott, Perkins, Diana, McEvoy, Joseph P., Lieberman, Jeffrey A., Sullivan, Patrick F., van den Oord, Edwin J.C.G.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2891163/
https://ncbi.nlm.nih.gov/pubmed/20195266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2010.14
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares